Online Sharing for Head & Neck Cancer Support

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, open-label trial will compare an intervention app that enables daily sharing, anonymous peer comments, likes, private messaging, psychoeducational resources, and reminders against usual care in 120 adults with head and neck squamous cell carcinoma undergoing radiotherapy. Participants are assigned 1:1 to either immediately receive the app or be placed on a waitlist with a paper psychoeducational booklet. The study aims to determine whether the digital platform can decrease anxiety and depression and improve quality of life during treatment. Outcomes will be measured through validated questionnaires over the treatment period and follow-up. The trial is conducted at West China Hospital and uses a parallel-group design with standard radiotherapy as background care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 - 75 years, male or female
2. Life expectancy ≥ 6 months
3. Histopathologically confirmed head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) without distant metastasis
4. Planned to receive curative radiotherapy or postoperative adjuvant radiotherapy
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
6. Adequate cognitive and reading ability to complete questionnaires
7. Ability to use a smartphone or tablet device
8. Fluent in Chinese (reading and speaking)
9. Willing and able to provide signed informed consent

Exclusion Criteria:

1. Other malignancies (except treated basal cell skin cancer or cervical CIS)
2. Prior head and neck radiotherapy
3. History of psychiatric disorder or psychotropic medication use
4. Absolute contraindication to head and neck radiotherapy
5. Uncontrolled systemic disease (poorly controlled DM, NYHA III-IV HF, interstitial lung disease)

Where it's running

• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Xingchen Peng
• Email: pxx2014@163.com
• Phone: +86 18980606753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer

  This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hebei, Hebei · NCT07906587

• ICG with near-infrared imaging to visualize head and neck cancer during surgery

  This study tests whether first-window indocyanine green fluorescence seen during surgery matches the cancer extent seen on pathology in patients with head and neck squamous cell carcinoma.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07825597

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer

  This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.

  Recruiting at 5 sites Phase 2 AbbVie · Duarte, California and 4 other locations · NCT07744126

• Mild heat therapy added to standard treatment for locally advanced head and neck cancer

  This early-stage trial tests whether mild hyperthermia can be safely added to standard radiotherapy with or without chemotherapy for locally advanced head and neck cancer.

  Recruiting Phase 1 Erasmus Medical Center · Rotterdam, South Holland · NCT07690618

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.